Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzon’s PEG-glucocerebrosidase

Executive Summary

IND filed for the treatment of Gaucher's disease. The company has been working with the National Institute of Mental Health, which developed glucocerebrosidase, under a Cooperative Research & Development Agreement signed in November 1991. The company's version of the recombinant compound is modified with Enzon's PEG- nology sustained-release technology, which it believes will allow smaller doses to be given at less frequent intervals than Genzyme's Cersdass. Enzon has completed a facility to supply the product for clinical trials.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel